SkQ1 did Not have significant effects on max life span in mice. They ran many tests and still no maxlife increases. The report stated “better quality of life” of older mice. But it demonstrated clinical efficacy in several diseases including glaucoma (clinical studies were all done in Russia). Over $40 million were spent over the years on developing this drug. V.P. Skulachev is an excellent reputable biochemist with encyclopedic knowledge. He is also one of the few remaining advocates of the programmed theory of aging. It was originally claimed that SkQ can interfere with the aging program.
Several companies are developing mitochondrially–targeted antioxidants including Murphy & Smith’s Antipodean (mitoQ), Colby Pharmaceuticals (MitoT), etc. So far the results were not very impressive. MitoQ missed expectations in the HepC trials. Colby developed its MitoTempol to kill prostate cancer cells and produced good clinical data.
But the major problem with these compounds is dosing. Therapeutic doses are almost homeopathic and doses an order of magnitude higher than therapeutic are toxic. It was not such a big problem for MitoT, which was licensed in from Colby by Adamis Pharmaceuticals after rigorous due diligence.